The main cause of disability following spinal injury is failure of axons to regenerate and reconnect the spinal cord with the brain. If patients with cord lesions are ever to make a full recovery some means will have to be found to restore ascending sensory and descending motor connections. Until the last few years there has been a very limited understanding of the reasons why axons in the central nervous system (eNS) fail to regenerate, but as a result of recent work the picture is now much clearer.
Why do axons fail to regenerate in the eNS?
The eNS environment is inhibitory to axon growth: this can be shown by transplanting eNS tissue into peripheral nerves where it forms a barrier to axon regeneration, or by observing sensory axons regenerating in the dorsal root towards the spinal cord, where they cease to grow exactly where they encounter eNS tissue.1-3 Peripheral nerve (PNS) tissue on the other hand strongly promotes axon regeneration, even from eNS neurons. Thus if a peripheral nerve graft is inserted into the eNS, eNS neurons which would never normally regenerate their axons do so for a considerable distance in the Schwann cell environment of the peripheral nerve. 4 What is the cause of the inhibitory nature of the eNS environment?
There appear to be 2 main factors. First, oligodendrocytes have on their surface molecules which are inhibitory to axonal growth cones. 5 Second, astrocytic tissues, as found in glial scars, are extremely hard for axons to penetrate, for reasons which are not yet fully established.6 In addition to eNS tissue discouraging axon regeneration, neurons themselves change, so that axons regenerating from adult neurons grow much less vigorously than axons from embryonic neurons: 7 the greater vigour of growth from embryonic neurons is one of the reasons why brain grafts are only successful if derived from embryonic donors. 8 What types of treatment are under development?
The 3 causes of failure of regeneration in the eNS are therefore the inhibitory surface of oligodendrocytes, the resistance of astro cytes to penetration by axons, and the decrease in the vigour of axon growth with age. What treatments are available which might neutralise or ameliorate these effects? The inhibitory effect of oligodendrocytes on axons is due to 2 partially identified molecules of 35 and 250 kD, whose effects in vitro can be neutralised by monoclonal antibodies. When these antibodies are ap plied to the lesioned rat spinal cord in vivo, some axons can be seen to regenerate past the lesion for distances of over 1 cm, much further than in control animals. Although the number of axons regenerating is too few to have much functional effect, the anti bodies are clearly making the eNS environ ment less inhibitory to axon growth. This might be arranged by insertion of a Schwann cell or peripheral nerve graft, positioned so as to channel a small number of axons from a point proximal to the injury to a particular level of the cord distal to the injury. The limitations of such grafts at present are that axons that grow through the graft cannot penetrate far enough into spinal cord tissue distal to the graft to make useful connections, and that the long axons from motor cortex and other higher centres tend to regenerate poorly in them.11 These problems can probably be partially allevi ated by a combination of treatments: neurotrophic factors to neuronal cell bodies and axons to enhance outgrowth, blockers of oligodendrocyte inhibition and astrocyte active factors to make it easier for regener ating axons leaving the graft to penetrate the spinal cord and make connections with appropriate spinal neurons. Trophic factors and blocking antibodies, being polypep tides, are unable to cross the blood brain barrier, and have a limited lifetime, which makes them very difficult to administer. Many pharmaceutical companies are pre sently working to develop trophic factor agonists which will be much easier to handle, and would make treatment much more practicable. Multiple treatments of the type outlined above are only starting to be investigated in animals, and will need some work before they are optimised. Practical application in spinally injured humans will be extremely difficult, and success will probably come in small increments; a sudden therapeutic leap to complete spinal cord regeneration seems unlikely based on current scientific pro gress. 
